EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
about
Recent advances of novel targeted therapy in non-small cell lung cancerAnticipating the 1,000 dollar genomeHuman genetics and genomics a decade after the release of the draft sequence of the human genomeProfiling critical cancer gene mutations in clinical tumor samplesKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibTranslatability scoring in drug development: eight case studiesInflammation and lung cancer: roles of reactive oxygen/nitrogen speciesGefitinib for advanced non-small cell lung cancerCancer pharmacogenomics: strategies and challengesDynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA)Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancersFAM83A confers EGFR-TKI resistance in breast cancer cells and in miceDownregulation and growth inhibitory role of FHL1 in lung cancerLyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cellsAnaplastic lymphoma kinase: signalling in development and diseaseA kinase-independent role for EGF receptor in autophagy initiationProtein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cellsEGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatmentPerturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsEpithelial membrane protein-1 is a biomarker of gefitinib resistance.Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinibTrials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and FutureCancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspiratesIntratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cellsEGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinibThe Cancer Genome Atlas Pan-Cancer analysis projectMolecular biology of lung cancer: clinical implicationsMolecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersRetroviral oncogenes: a historical primerFrom combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathwayImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsClinical use of crizotinib for the treatment of non-small cell lung cancerCirculating tumor cells: approaches to isolation and characterizationPhosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitorsMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibSomatic mutations affect key pathways in lung adenocarcinomaSomatic mutations of the epidermal growth factor receptor and non-small-cell lung cancerThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
P2860
Q21092930-12391627-E8E6-41BE-B05D-4612532D5207Q21184143-A414FA38-206D-4548-A2CB-81F33264A9E8Q21245451-D2F80E5A-B487-4600-B8C1-EA07145C97F1Q21562343-2233035F-5163-4568-BB76-FFC2070E1F64Q21563446-64B9D041-EA36-4B71-82EA-CFD72B903DD7Q22241760-2CC987D7-D4C3-442D-A146-BF6477B79E35Q23918826-40C0BB96-C2B9-429D-B29D-F2F5EE590A1EQ24243064-E5C3B0CC-F8FA-4656-BEB8-926D825AEA77Q24289309-99D5E0DB-B2B3-4283-9A8A-4FFF2785C27CQ24294659-CD8109DA-36C3-4AB4-B0EA-4EFEC2A4962AQ24294953-0A2F33D4-762F-4FE9-912C-91CBE2859F4AQ24296333-63E0CA34-9493-451D-B336-74C9FD56AD79Q24307767-387919A8-1D9C-4DE0-9F9B-F80D639304BDQ24309725-784926B6-D1B0-4DE9-8E6C-C9478CDE9DABQ24312329-61AD3E81-C3C1-4138-9804-DC8EBA1D5716Q24314943-F35EB249-23D3-4E6C-AED8-C9367DB9A5D6Q24337213-A06137EA-E5DF-4D59-A165-7B2D2C67BFB7Q24338426-C56BA8BA-7684-4C09-98D5-21D2CCFB730DQ24339394-0C9965CD-4B8E-42FA-8FA5-8AA291C0590BQ24535592-56056DA3-B40D-412D-A9B6-F846B4FB695DQ24541450-4AD0DE9E-7962-4F37-9DD8-5EEA17F85276Q24561953-B287D22C-7DC1-4458-B1F8-CC1F1D70E321Q24564024-7380CB2A-32A1-4FD9-80D9-B5E082D4701BQ24564079-2E528065-8743-40A2-AA7D-44402A8C559DQ24603941-19324B4E-7670-4B63-9E1F-22F8CAC1AF3FQ24606177-E888ADA9-CCBF-45A5-A4FB-D202FAA83E3EQ24606808-FD6E78D0-B5D0-4411-9156-808EF891B0ABQ24610335-4C292265-3A4F-42AC-A7C8-5A5915981789Q24611043-5F22B0EE-6748-416F-B898-677F7E0707E1Q24611142-CF532EC3-E4BF-4B1E-A6CB-E614672E6AB3Q24621007-DBA8B262-54AC-4871-9D2D-86C5D89454D1Q24625201-88CC5A06-78F9-412C-BC26-0D7DB218C486Q24630466-A8696FD6-B07C-4B99-BF7A-11DC59B742F8Q24631347-2C6DA092-5BA4-4F5E-918A-E2FBEA0266E5Q24644787-9F9440B6-D026-4240-8D65-DD1B8F543D14Q24646295-6B4A84C8-3579-4C70-BD48-821A594959F5Q24648102-4CCCC87A-EBCE-4061-9BC2-9931F0D711D5Q24648133-60B2F075-3DD2-4D82-86A9-853EE8C5EBF0Q24649549-31AD296C-F354-4AEA-9932-8A9F2039D4F0Q24649935-15DEDB73-EAB3-414A-9CAB-7FF509115034
P2860
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@ast
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@en
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@nl
type
label
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@ast
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@en
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@nl
altLabel
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
@en
prefLabel
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@ast
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@en
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@nl
P2093
P50
P3181
P356
P1433
P1476
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
@en
P2093
Bruce E Johnson
Frederic J Kaye
Hidefumi Sasaki
J Guillermo Paez
Jeffrey C Lee
Katsuhiko Naoki
Michael J Eck
Neal Lindeman
Paula Herman
Sean Tracy
P304
P3181
P356
10.1126/SCIENCE.1099314
P407
P577
2004-06-04T00:00:00Z